BRISTOL-MYERS SQUIBB COMPANY lobbying for BRISTOL-MYERS SQUIBB COMPANY

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $4,780,000.00 expenses · posted Jul 21, 2025

Official filing document

Bills named in this filing 8

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 864
HELP Copays Act
S 526
Pharmacy Benefit Manager Transparency Act of 2025
HR 3521
Clinical Trial Modernization Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
HR 3285
Fairness for Patient Medications Act
S 1339
Pharmacy Benefit Manager Reform Act

Lobbying activity 6

Health Issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions

Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Issues related to the six protected classes of medicines under Medicare Part D, regarding all bio-pharmaceutical issues

Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Copyright/Patent/Trademark

Intellectual Property Reform concerning bio-pharmaceutical industry

Pharmacy

S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968

Trade (domestic/foreign)

International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues